Mubadala Bio Emerges As Pillar Of UAE's Healthcare Vision

(MENAFN- The Arabian Post) Arabian Post Staff -Dubai

Mubadala Investment Company has unveiled Mubadala Bio, a new life sciences entity designed to bolster the United Arab Emirates' pharmaceutical manufacturing capabilities and enhance healthcare resilience. The initiative aligns with the country's Centennial 2071 vision, aiming to position Abu Dhabi as a regional hub for biopharmaceutical innovation.

Mubadala Bio's infrastructure encompasses ten facilities across Asia, Africa, and Europe, with six situated within the UAE. Collectively, these sites span 110,000 square metres and possess an annual production capacity exceeding 2.5 billion tablets and capsules, along with 120 million intravenous and injectable units. The company's extensive portfolio includes over 10,000 medical products, serving more than 100 countries worldwide.

The company's focus extends across the entire continuum of care, from prevention and diagnostics to treatment and supportive therapies. This comprehensive approach aims to address pressing global health challenges and improve patient outcomes.

Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform, stated that the launch of Mubadala Bio represents a transformative step toward strengthening national drug security and fostering innovation in life sciences. He emphasized that this positions Mubadala at the forefront of the industry, enabling long-term economic growth and the development of a resilient life sciences ecosystem.

Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala, highlighted the company's commitment to supporting the UAE's ambition to become a global leader in the life sciences industry. By focusing on local manufacturing and enhancing distribution and logistics capabilities, Mubadala Bio aims to build a self-sustaining sector prepared for future challenges.

Mubadala Bio plans to establish strategic partnerships with global life sciences firms and academic institutions to accelerate biopharmaceutical innovation and nurture world-class talent within the UAE. These collaborations are intended to drive advancements in healthcare and support the country's transition to a knowledge-based economy.

See also AURAK Study Urges Greater Awareness of Enterovirus Threats in Gulf

The company's launch will be formally introduced at the upcoming Make it in the Emirates 2025 event, showcasing the UAE's success in building a competitive life sciences industry. This event serves as a national industrial showcase, reinforcing the country's position as a hub for innovation and local manufacturing.

Mubadala Bio is designated as one of Mubadala's“National Champions,” entities established to support strategic sectors aligned with the UAE's long-term development goals. Through its initiatives, the company aims to accelerate the UAE's economic diversification, particularly in healthcare and biotechnology.

Notice an issue? Arabian Post strives to deliver the most accurate and reliable information to its readers. If you believe you have identified an error or inconsistency in this article, please don't hesitate to contact our editorial team at editor[at]thearabianpost[dot]com . We are committed to promptly addressing any concerns and ensuring the highest level of journalistic integrity.

MENAFN20052025000152002308ID1109570347